Unveiling of Pars Isotope’s latest products at the National Nuclear Technology Festival
Pars Isotope’s latest products in the field of PET imaging were unveiled at the 16th National Nuclear Technology Festival, with the presence of the President, the Vice President, the Head of the Atomic Energy Organization, and a group of ministers and high-ranking officials on Saturday, April 9, 2022.
Ga-68-CIXAFOR, Ga-68-FAPI radiopharmaceuticals and Ge-68 Phantom are three new products of Pars Isotope, all of which are related to the PET imaging system.
Ga-68-CIXAFOR diagnostic radiopharmaceutical produced under the brand name of PARS-CIXAFOR is used to diagnose more than 30 different types of cancer, including lymphoma, breast, pancreas, ovary, and lung cancer (SCLC), etc., as well as a kind of brain tumor, called glioblastoma. The design, development, and production of this radiopharmaceutical have provided the basis for diagnosing various types of cancer, which will result in the appropriate selection of treatment methods for these cancers. CXCR4 is a kind of receptor found on the surface of cancerous cells. PARS-CIXAFOR radiopharmaceutical binds to this receptor, and it can be used for highly accurate and intelligent PET imaging for diagnosing more than 30 types of cancer.
Ga-68-FAPI radiopharmaceutical production technology has been developed based on the advancement and improvement in healthcare and life expectancy. This radiopharmaceutical is used to diagnose and treat cancer and incurable diseases.
The design and development of this radiopharmaceutical have made the diagnosis of more than 30 types of cancer, including the brain, breast, esophagus, colon, liver, lung, mouth, ovary, pancreas, kidney, etc., possible. The expression of differentiated fibroblasts on cancer cells is one of their significant characteristics, and one of their main attributes is the expression of Fibroblast Activation Protein (FAP). The expression of this protein on the cell surface is the sign to tell the cancerous and non-cancerous cells apart. This radiopharmaceutical binds intelligently and selectively to the surface of cancerous cells on which the FAP protein is expressed. This radiopharmaceutical has the ability to diagnose more than 30 types of cancer using the PET imaging system with high accuracy and intelligence and will help the doctor to choose the appropriate treatment.
A positron emission tomography (PET) scanner is one of the most modern, accurate and advanced nuclear medicine imaging systems with unparalleled capabilities for diagnosing different types of cancer and disease. In order to have a proper functioning imaging system, the machine needs to be calibrated and adjusted on a daily basis. This calibrations require a particular set of tools. The Germanium-68 Cylindrical Phantom is one of the tools that is used to perform the daily functional testing.
Regarding the production of these products, now Iran is among the limited group of countries capable of producing these particular radiopharmaceutical products. Pars Isotope as the exclusive manufacturer of diagnostic and therapeutic radiopharmaceuticals and radiopharmaceutical kits in Iran, always strives to promote the public health in the community by developing new, up-to-date and efficient products.